125 related articles for article (PubMed ID: 12769667)
21. Analysis of tamoxifen and 4-hydroxytamoxifen levels in immature rat uterine cytoplasm and KCl-nuclear extracts by gas chromatography-mass spectrometry (GC-MS) using selected ion monitoring (SIM).
Murphy C; Fotsis T; Adlercreutz H; Martin F
J Steroid Biochem; 1987 Sep; 28(3):289-99. PubMed ID: 3657151
[TBL] [Abstract][Full Text] [Related]
22. Induction of hepatic aneuploidy in vivo by tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats.
Sargent LM; Dragan YP; Sattler C; Bahnub N; Sattler G; Martin P; Cisneros A; Mann J; Thorgeirsson S; Jordan VC; Pitot HC
Carcinogenesis; 1996 May; 17(5):1051-6. PubMed ID: 8640912
[TBL] [Abstract][Full Text] [Related]
23. Peroxidase activation of 4-hydroxytamoxifen to cause DNA damage in vitro.
Davies AM; Malone ME; White IN
Biochem Soc Trans; 1995 Aug; 23(3):439S. PubMed ID: 8566328
[No Abstract] [Full Text] [Related]
24. Identification of tamoxifen-DNA adducts induced by alpha-acetoxy-N-desmethyltamoxifen.
Kitagawa M; Ravindernath A; Suzuki N; Rieger R; Terashima I; Umemoto A; Shibutani S
Chem Res Toxicol; 2000 Aug; 13(8):761-9. PubMed ID: 10956064
[TBL] [Abstract][Full Text] [Related]
25. 4-Hydroxylated metabolites of the antiestrogens tamoxifen and toremifene are metabolized to unusually stable quinone methides.
Fan PW; Zhang F; Bolton JL
Chem Res Toxicol; 2000 Jan; 13(1):45-52. PubMed ID: 10649966
[TBL] [Abstract][Full Text] [Related]
26. Preclinical data for Droloxifene.
Hasmann M; Rattel B; Löser R
Cancer Lett; 1994 Sep; 84(2):101-16. PubMed ID: 8076367
[TBL] [Abstract][Full Text] [Related]
27. Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.
Antunes MV; Timm TA; de Oliveira V; Staudt DE; Raymundo S; Gössling G; Biazús JV; Cavalheiro JA; Rosa DD; Wallemacq P; Haufroid V; Linden R; Schwartsmann G
Ther Drug Monit; 2015 Dec; 37(6):733-44. PubMed ID: 25853922
[TBL] [Abstract][Full Text] [Related]
28. Idoxifene: report of a phase I study in patients with metastatic breast cancer.
Coombes RC; Haynes BP; Dowsett M; Quigley M; English J; Judson IR; Griggs LJ; Potter GA; McCague R; Jarman M
Cancer Res; 1995 Mar; 55(5):1070-4. PubMed ID: 7866990
[TBL] [Abstract][Full Text] [Related]
29. Induction of transforming growth factor beta by the antiestrogens droloxifene, tamoxifen, and toremifene in MCF-7 cells.
Knabbe C; Zugmaier G; Schmahl M; Dietel M; Lippman ME; Dickson RB
Am J Clin Oncol; 1991; 14 Suppl 2():S15-20. PubMed ID: 1835818
[TBL] [Abstract][Full Text] [Related]
30. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
O'Regan RM; Cisneros A; England GM; MacGregor JI; Muenzner HD; Assikis VJ; Bilimoria MM; Piette M; Dragan YP; Pitot HC; Chatterton R; Jordan VC
J Natl Cancer Inst; 1998 Oct; 90(20):1552-8. PubMed ID: 9790548
[TBL] [Abstract][Full Text] [Related]
31. Oxo substituents markedly alter the phase II metabolism of alpha-hydroxybutenylbenzenes: models probing the bioactivation mechanisms of tamoxifen.
Ramakrishna KV; Fan PW; Boyer CS; Dalvie D; Bolton JL
Chem Res Toxicol; 1997 Aug; 10(8):887-94. PubMed ID: 9282838
[TBL] [Abstract][Full Text] [Related]
32. Tamoxifen: evidence by 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite.
Randerath K; Moorthy B; Mabon N; Sriram P
Carcinogenesis; 1994 Oct; 15(10):2087-94. PubMed ID: 7955037
[TBL] [Abstract][Full Text] [Related]
33. Activation of tamoxifen and its metabolite alpha-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes.
Phillips DH; Carmichael PL; Hewer A; Cole KJ; Hardcastle IR; Poon GK; Keogh A; Strain AJ
Carcinogenesis; 1996 Jan; 17(1):89-94. PubMed ID: 8565142
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and reactivity of potential toxic metabolites of tamoxifen analogues: droloxifene and toremifene o-quinones.
Yao D; Zhang F; Yu L; Yang Y; van Breemen RB; Bolton JL
Chem Res Toxicol; 2001 Dec; 14(12):1643-53. PubMed ID: 11743747
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and investigation of alpha-hydroxy-N,N-didesmethyltamoxifen as a proximate carcinogen in the metabolic activation of tamoxifen.
Gamboa da Costa G; Marques MM; Freeman JP; Beland FA
Chem Res Toxicol; 2003 Sep; 16(9):1090-8. PubMed ID: 12971796
[TBL] [Abstract][Full Text] [Related]
36. The effect of tamoxifen and two of its non-isomerizable fixed-ring analogs on multistage rat hepatocarcinogenesis.
Dragan YP; Fahey S; Nuwaysir E; Sattler C; Babcock K; Vaughan J; McCague R; Jordan VC; Pitot HC
Carcinogenesis; 1996 Mar; 17(3):585-94. PubMed ID: 8631149
[TBL] [Abstract][Full Text] [Related]
37. An electrochemical outlook on tamoxifen biotransformation: current and future prospects.
Garrido JM; Manuela E; Garrido PJ; Oliveira-Brett AM; Borges F
Curr Drug Metab; 2011 May; 12(4):372-82. PubMed ID: 21395526
[TBL] [Abstract][Full Text] [Related]
38. 4-Hydroxytamoxifen sulfation metabolism.
Chen G; Yin S; Maiti S; Shao X
J Biochem Mol Toxicol; 2002; 16(6):279-85. PubMed ID: 12481303
[TBL] [Abstract][Full Text] [Related]
39. Lack of genotoxicity of tamoxifen in human endometrium.
Carmichael PL; Ugwumadu AH; Neven P; Hewer AJ; Poon GK; Phillips DH
Cancer Res; 1996 Apr; 56(7):1475-9. PubMed ID: 8603387
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice.
Gutman M; Couillard S; Roy J; Labrie F; Candas B; Labrie C
Int J Cancer; 2002 May; 99(2):273-8. PubMed ID: 11979444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
